Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Fibrate Drugs Market Valued at Present and by 2029?

The market size for fibrate drugs has been experiencing constant growth over the past few years. The market is projected to increase from $3.49 billion in 2024 to $3.58 billion in 2025, with a compound annual growth rate (CAGR) of 2.8%. The historical growth has been influenced by factors such as focus on lipid and cholesterol management, extensive clinical research and trials, reduction in cardiovascular risks, and the use of combination therapies.

The market size of fibrates drugs is projected to witness robust growth in the coming years, swelling to “$4.72 billion in 2029 with a compound annual growth rate (CAGR) of 7.2%.” This projected growth during the forecast period can be credited to ongoing updates in treatment protocols, an emphasis on residual risk, advancements in precision medicine, and innovation in drug distribution methods. Key future trends include the exploration of alternative drug formulations, the integration of telemedicine, the use of fibrates in high-risk groups, efforts to target triglyceride levels, and an enhanced focus on increasing HDL levels.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11932&type=smp

#What Drivers Are Influencing Growth In The Fibrate Drugs Market?

The escalating occurrences of cardiac diseases are anticipated to fuel the progression of the fibrate drug market. Cardiac diseases comprise a variety of conditions that impact the heart and blood vessels, including congenital heart disease, coronary heart disease, and more. Fibrates act as a preventative measure against further heart attacks and strokes in individuals who already have a circulatory system condition, which contributes to the advancement of the fibrate drug market. For example, the Singapore Heart Foundation (SHF) reported that ischemic heart diseases caused 5,302 deaths in May 2024, a minor increase from 5,290 deaths in 2022. Moreover, the overall death rate due to hypertensive diseases rose to 3.7% in 2022 from 3.4% the previous year. Consequently, the rising prevalence of cardiac diseases is propelling the fibrate drug market’s expansion.

The fibrate drugs market covered in this report is segmented –

1) By Drug Type: Clofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil, Other Drugs

2) By Indication: Hypercholesterolemia, Heart Attacks, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Clofibrate: Standard Clofibrate, Combination Products

2) By Fenofibrates: Fenofibrate Capsules, Fenofibrate Tablets, Combination Products

3) By Fenofibric Acids: Fenofibric Acid Capsules, Combination Products

4) By Gemfibrozil: Standard Gemfibrozil, Combination Products

5) By Other Drugs: Other Fibrate Formulations, Emerging Fibrate Drugs

What Future Market Trends Are Projected For The Fibrate Drugs Industry?

Major players in the fibrate drugs market are concentrating their efforts on the advancement of new solutions like fixed-dose combinations to retain their market dominance. A fixed-dose combination is defined as a single dose formulation containing more than one active ingredient, which simplifies the administration process and potentially enhances the therapeutic results. For example, in May 2023, Intercept Pharmaceuticals Inc., a US-based biopharmaceutical company, earned the U.S. Food and Drug Administration (FDA) approval for an orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate. The combination, which is a peroxisome proliferator-activated receptor (PPAR) agonist, is under investigation for the potential treatment of individuals with primary biliary cholangitis (PBC). OCA, a farnesoid X receptor (FXR) agonist, is currently being marketed as Ocaliva by Intercept in the United States for PBC treatment, whereas bezafibrate, a pan-PPAR agonist, does not have approval in the United States for any indication at present.

Which Companies Play A Key Role In The Development Of The Fibrate Drugs Market?

Major companies operating in the fibrate drugs market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Bristol-Myers Squibb Co, Abbott Laboratories, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Zydus Lifesciences Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd., Natco Pharma, Hetero Drugs Ltd

https://www.thebusinessresearchcompany.com/report/fibrate-drugs-global-market-report

What Are The Key Regional Developments Shaping The Fibrate Drugs Market?

North America was the largest region in the fibrate drugs market in 2024. The regions covered in the fibrate drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11932&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model